Morpholine → HCID 57929959, compound
Reaction equation
CS(O[CH2:6][CH2:7][N:8]1[CH:12]=[C:11]([C:13]2[CH:14]=[CH:15][C:16]3[N:17]([C:19]([CH:22]([CH3:24])[CH3:23])=[N:20][N:21]=3)[N:18]=2)[C:10]([C:25]2[CH:30]=[CH:29][C:28]([F:31])=[CH:27][C:26]=2[F:32])=[N:9]1)(=O)=O.[NH:33]1[CH2:38][CH2:37][O:36][CH2:35][CH2:34]1>CO>[F:32][C:26]1[CH:27]=[C:28]([F:31])[CH:29]=[CH:30][C:25]=1[C:10]1[C:11]([C:13]2[CH:14]=[CH:15][C:16]3[N:17]([C:19]([CH:22]([CH3:23])[CH3:24])=[N:20][N:21]=3)[N:18]=2)=[CH:12][N:8]([CH2:7][CH2:6][N:33]2[CH2:38][CH2:37][O:36][CH2:35][CH2:34]2)[N:9]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Conditions
- Temperature
- 70 °C
Procedure
The 2-(3-(2,4-difluorophenyl)-4-(3-isopropyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-1-yl)ethyl methanesulfonate (0.24 g, 0.52 mmol; Preparation #W.1) was dissolved in MeOH (4 mL) then morpholine (0.36 g, 4.2 mmol) was added. The mixture was heated at about 70° C. in an oil bath for about 2 h then cooled and concentrated under reduced pressure. The crude material was purified by RP-HPLC (Table 1, Method d). The appropriate fractions were concentrated under reduced pressure then basified with 2 N NaOH. Extraction of the solution with EtOAc followed by drying of the organic extract over MgSO4 and then filtration prior to concentrating under reduced pressure gave the title compound (0.10 g, 43%): LC/MS (Table 1, Method a) Rt=2.09 min; MS m/z: 454.2 (M+H)+.
Workup
- temperaturethen cooled
- concentrationconcentrated under reduced pressure
- customThe crude material was purified by RP-HPLC (Table 1, Method d)
- concentrationThe appropriate fractions were concentrated under reduced pressure
- extractionExtraction of the solution with EtOAc
- customby drying of the
- extractionorganic extract over MgSO4
- filtrationfiltration
- concentrationto concentrating under reduced pressure
Sources & evidence
- ORD record
- ord-848b6908dfc442ec91c2b53f4239de51
- Source dataset
- uspto-grants-2012_05
- Patent number
- US08188083B2
Reaction notes
Loading…